Your browser doesn't support javascript.
loading
Impact of prophylaxis on health-related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries.
Usuba, Koyo; Price, Victoria E; Blanchette, Victor; Abad, Audrey; Altisent, Carmen; Buchner-Daley, Loretta; Carneiro, Jorge D A; Feldman, Brian M; Fischer, Kathelijn; Grainger, John; Holzhauer, Susanne; Luke, Koon-Hung; Meunier, Sandrine; Ozelo, Margareth; Tang, Ling; Antunes, Sandra V; Villaça, Paula; Wakefield, Cindy; Wharfe, Gilian; Wu, Runhui; Young, Nancy L.
Afiliación
  • Usuba K; Child Health Evaluative Sciences Program, Research Institute The Hospital for Sick Children (SickKids) Toronto Ontario Canada.
  • Price VE; Evaluating Children's Health Outcomes Research Centre Laurentian University Sudbury Ontario Canada.
  • Blanchette V; Division of Pediatric Hematology/Oncology Department of Pediatrics IWK Health Centre Dalhousie University Halifax Nova Scotia Canada.
  • Abad A; Division of Hematology/Oncology Department of Pediatrics The Hospital for Sick Children (SickKids) University of Toronto Toronto Ontario Canada.
  • Altisent C; Child Health Evaluative Sciences Program, Research Institute The Hospital for Sick Children (SickKids) Toronto Ontario Canada.
  • Buchner-Daley L; Unitat Hemofilia Hospital Vall d'Hebron Barcelona Spain.
  • Carneiro JDA; Department of Pathology University of the West Indies (UWI) Mona Jamaica.
  • Feldman BM; Centro de Hemofilia e Instituto da Criança Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo São Paulo Brazil.
  • Fischer K; Division of Rheumatology The Hospital for Sick Children Toronto Ontario Canada.
  • Grainger J; Institute of Health Policy Management & Evaluation, the Dalla Lana School of Public Health University of Toronto Toronto Ontario Canada.
  • Holzhauer S; Van Creveldkliniek University Medical Center Utrecht Utrecht The Netherlands.
  • Luke KH; Royal Manchester Children's Hospital Manchester UK.
  • Meunier S; Department of Pediatric Hematology and Oncology Charité University Medicine Berlin Germany.
  • Ozelo M; Department of Pediatrics Laboratory Medicine and Pathology University of Ottawa Ottawa Ontario Canada.
  • Tang L; Hemostase Clinique Groupement Hospitalier Universitaire Est Hospices Civils de Lyon Bron France.
  • Antunes SV; Unit of Hemophilia IHTC Cláudio L.P. Correa Hemocentro Unicamp INCT do Sangue University of Campinas Campinas Brazil.
  • Villaça P; Hematology/Oncology Center Beijing Children's Hospital, Capital Medical University Beijing China.
  • Wakefield C; Department of Hematology Universidade Federal de São Paulo (UNIFESP) São Paulo Brazil.
  • Wharfe G; Service of Hematology Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo São Paulo Brazil.
  • Wu R; Department of Nursing The Hospital for Sick Children (SickKids) Toronto Ontario Canada.
  • Young NL; Department of Pathology University of the West Indies (UWI) Mona Jamaica.
Res Pract Thromb Haemost ; 3(3): 397-404, 2019 Jul.
Article en En | MEDLINE | ID: mdl-31294327
BACKGROUND: Prophylaxis reduces the frequency of bleeds in boys with severe hemophilia and is the standard care for their management in resource-abundant countries. The effect of prophylaxis on Health-Related Quality of Life (HRQoL) has not been established, because the sample sizes of most studies are too small to explore the relationship of multiple factors that influence HRQoL. METHODS: The aim of this study was to assess the impact of hemophilia severity and treatment regimen on HRQoL and to establish the minimum important difference (MID) using the international level of score distributions. HRQoL data were pooled from 7 studies across 9 countries. HRQoL was measured using the Canadian Hemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT). A mixed-effect linear regression analysis was employed to assess the impact of prophylaxis on the CHO-KLAT score. RESULTS: Data from 401 boys with hemophilia were analyzed (57.6% severe hemophilia and 57.6% receiving prophylaxis). The model revealed that receiving prophylaxis was significantly associated with higher HRQoL (regression coefficient 8.5, 95% confidence interval [CI] 3.9-13.1). Boys with severe hemophilia had a significantly lower HRQoL as compared to boys with moderate and mild hemophilia whose CHO-KLAT scores were 7.0 and 6.6 points higher, respectively. There was a significant interaction between treatment and disease severity (P = 0.023), indicating prophylaxis has the most significant impact in boys with severe hemophilia. Based on these pooled data, the MID of the CHO-KLAT was established at 6.5. CONCLUSIONS: This study confirms the positive effect of prophylaxis on HRQoL in boys with hemophilia in a real-world setting and provides initial benchmarks for interpreting HRQoL scores based on use of the CHO-KLAT instrument.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Res Pract Thromb Haemost Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Res Pract Thromb Haemost Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos